Información del artículo
Resumen
La sepsis es un problema de salud pública de ámbito mundial que genera un alto número de consultas y hospitalizaciones anuales. A pesar de los avances en la medicina moderna sigue siendo la principal causa de muerte en el paciente crítico. Hace varias décadas se ha impulsando el desarrollo de biomarcadores a fin de lograr un diagnóstico temprano y un seguimiento oportuno y adecuado de la infección bacteriana. La procalcitonina en el año 2008 fue propuesta como un marcador diagnóstico para diferenciar la infección bacteriana de otros estados inflamatorios, posteriormente se ha empleado como guía de la terapia antimicrobiana en diferentes escenarios y en los últimos años se ha evaluado como marcador pronóstico. El presente artículo es una revisión narrativa de la procalcitonina como herramienta diagnóstica, guía de la terapia antimicrobiana y marcador pronóstico en pacientes críticos.
Palabras clave:
Calcitonina
Procalcitonina
Cuidado intensivo
Diagnóstico
Sepsis
Abstract
Sepsis is a public health problem worldwide, it generates a high number of annual consultations and hospitalizations. Despite advances in modern medicine, it remains the leading cause of death in the critical patient. Several decades ago the development of biomarkers has been promoted in order to achieve an early diagnosis and timely and adequate follow-up of the bacterial infection. Procalcitonin (PCT) in 2008 was proposed as a diagnostic marker to differentiate bacterial infection from other inflammatory conditions, subsequently it has been used as a guide for antimicrobial therapy in different scenarios and in recent years it has been evaluated as a prognostic marker. This article is a narrative review of procalcitonin as a diagnostic tool, a guide to antimicrobial therapy and a prognostic marker in critical patients.
Keywords:
Calcitonin
Procalcitonin
Intensive care
Diagnosis
Sepsis
Artículo
Opciones para acceder a los textos completos de la publicación Acta Colombiana de Cuidado Intensivo
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
C.M. Coopersmith, D. de Backer, C.S. Deutschman, R. Ferrer, I. Lat, F.R. Machado, et al.
Surviving sepsis campaign: Research priorities for sepsis and septic shock.
Crit Care Med, 46 (2018), pp. 1334-1356
[2]
B.D. Winters, M. Eberlein, J. Leung, D.M. Needham, P.J. Pronovost, J.E. Sevransky.
Long-term mortality and quality of life in sepsis: A systematic review.
Crit Care Med, 38 (2010), pp. 1276-1283
[3]
M.C. Strehlow, S.D. Emond, N.I. Shapiro, A.J. Pelletier, C.A. Camargo.
National study of emergency department visits for sepsis, 1992 to 2001.
Ann Emerg Med, 48 (2006), pp. 326-331
[4]
E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, et al.
Early goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med, 345 (2001), pp. 1368-1377
[5]
A. Clerico, M. Plebani.
Biomarkers for sepsis: An unfinished journey.
Clin Chem Lab Med, 51 (2013), pp. 1135-1138
[6]
M.E. Niño-Mantilla, C.M. Hormiga-Sánchez, I.T. Ordoñez, V.P. Villarreal-Ibarra, L. Ardila-Acuña, D. Torres-Dueñas.
Mortalidad por sepsis e infecciones complicadas en el departamento de Santander Colombia.
Universidad y Salud, 16 (2014), pp. 139-149
[7]
F. Jaimes, J. Garcés, J. Cuervo, F. Ramírez, J. Ramírez, A. Vargas, et al.
The systemic inflammatory response syndrome (SIRS) to identify infected patients in the emergency room.
Intensive Care Med, 29 (2003), pp. 1368-1371
[8]
B.M. Biron, A. Ayala, J.L. Lomas-Neira.
Biomarkers for sepsis: What is and what might be?.
Biomark Insights, 10 (2015), pp. 7-17
[9]
M.M. Levy, M.P. Fink, J.C. Marshall, E. Abraham, D. Angus, D. Cook, et al.
2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference.
Crit Care Med, 31 (2003), pp. 1250-1256
[10]
N.P. O’Grady, P.S. Barie, J.G. Bartlett, T. Bleck, K. Carroll, A.C. Kalil, et al.
Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America.
Crit Care Med, 36 (2008), pp. 1330-1349
[11]
N. Bréchot, G. Hékimian, J. Chastre, C.E. Luyt.
Procalcitonin to guide antibiotic therapy in the ICU.
Int J Antimicrob Agents, 46 (2015), pp. S19-S24
[12]
B.M.P. Tang, G.D. Eslick, J.C. Craig, A.S. McLean.
Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis.
Lancet Infect Dis, 7 (2007), pp. 210-217
[13]
B. Uzzan, R. Cohen, P. Nicolas, M. Cucherat, G.Y. Perret.
Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis.
Crit Care Med, 34 (2006), pp. 1996-2003
[14]
A. Rhodes, L.E. Evans, W. Alhazzani, M.M. Levy, M. Antonelli, R. Ferrer, et al.
Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016.
Intensive Care Med, 43 (2017), pp. 304-377
[15]
I. Samsudin, S.D. Vasikaran.
Clinical utility and measurement of procalcitonin.
Clin Biochem Rev, 38 (2017), pp. 59-68
[16]
P. Schuetz, R. Bolliger, M. Merker, M. Christ-Crain, D. Stolz, M. Tamm, et al.
Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials.
Expert Rev Anti Infect Ther, 16 (2018), pp. 555-564
[17]
M. Prucha, G. Bellingan, R. Zazula.
Sepsis biomarkers.
Clin Chim Acta, 440 (2015), pp. 97-103
[18]
D. Nora, J. Salluh, I. Martin-Loeches, P. Póvoa.
Biomarker-guided antibiotic therapy-strengths and limitations.
Ann Transl Med, 5 (2017), pp. 208
[19]
S. Stoppelkamp, K. Veseli, K. Stang, C. Schlensak, H.P. Wendel, T. Walker.
Identification of predictive early biomarkers for sterile-SIRS after cardiovascular surgery.
PLOS ONE, 10 (2015), pp. e0135527
[20]
J.H. Han, I. Nachamkin, S.E. Coffin, J.S. Gerber, B. Fuchs, C. Garrigan, et al.
Use of a combination biomarker algorithm to identify medical intensive care unit patients with suspected sepsis at very low likelihood of bacterial infection.
Antimicrob Agents Chemother, 59 (2015), pp. 6494-6500
[21]
C. Wacker, A. Prkno, F.M. Brunkhorst, P. Schlattmann.
Procalcitonin as a diagnostic marker for sepsis: A systematic review and meta-analysis.
Lancet Infect Dis, 13 (2013), pp. 426-435
[22]
M. Limper, M.D. de Kruif, A.J. Duits, D.P.M. Brandjes, E.C.M. van Gorp.
The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever.
J Infect, 60 (2010), pp. 409-416
[23]
A. Hohn, B. Heising, J.K. Schütte, O. Schroeder, S. Schröder.
Procalcitonin-guided antibiotic treatment in critically ill patients.
Langenbecks Arch Surg, 402 (2017), pp. 1-13
[24]
D. Stolz, N. Smyrnios, P. Eggimann, H. Pargger, N. Thakkar, M. Siegemund, et al.
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: A randomised study.
Eur Respir J, 34 (2009), pp. 1364-1375
[25]
L. Bouadma, C.E. Luyt, F. Tubach, C. Cracco, A. Alvarez, C. Schwebel, et al.
Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial.
Lancet, 375 (2010), pp. 463-474
[26]
J.U. Jensen, L. Hein, B. Lundgren, M.H. Bestle, T.T. Mohr, M.H. Andersen, et al.
Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial.
Crit Care Med, 39 (2011), pp. 2048-2058
[27]
D. Liu, L. Su, G. Han, P. Yan, L. Xie.
Prognostic value of procalcitonin in adult patients with sepsis: A systematic review and meta-analysis.
PLOS ONE, 10 (2015), pp. e0129450
[28]
S. Arora, P. Singh, P.M. Singh, A. Trikha.
Procalcitonin levels in survivors and nonsurvivors of sepsis: Systematic review and meta-analysis.
Shock, 43 (2015), pp. 212-221
[29]
A. Prkno, C. Wacker, F.M. Brunkhorst, P. Schlattmann.
Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.
Crit Care, 17 (2013), pp. R291
[30]
C. Corti, M. Fally, A. Fabricius-Bjerre, K. Mortensen, B.N. Jensen, H.F. Andreassen, et al.
Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD.
Int J Chron Obstruct Pulmon Dis, 11 (2016), pp. 1381-1389
[31]
M. Leone, L. Bouadma, B. Bouhemad, O. Brissaud, S. Dauger, S. Gibot, et al.
Hospital-acquired pneumonia in ICU.
Anaesth Crit Care Pain Med, 37 (2018), pp. 83-98
[32]
Y. Wirz, M.A. Meier, L. Bouadma, C.E. Luyt, M. Wolff, J. Chastre, et al.
Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: A patient-level meta-analysis of randomized trials.
Crit Care, 22 (2018), pp. 191
[33]
D.K. Matthaiou, G. Ntani, M. Kontogiorgi, G. Poulakou, A. Armaganidis, G. Dimopoulos.
An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.
Intensive Care Med, 38 (2012), pp. 940-949
[34]
R. Pugh, C. Grant, R.P.D. Cooke, G. Dempsey.
Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.
Cochrane Database Syst Rev, (2015), pp. CD007577
[35]
P. Kopterides, I.I. Siempos, I. Tsangaris, A. Tsantes, A. Armaganidis.
Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials.
Crit Care Med, 38 (2010), pp. 2229-2241
[36]
P. Schuetz, Y. Wirz, R. Sager, M. Christ-Crain, D. Stolz, M. Tamm, et al.
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.
Cochrane Database Syst Rev [Internet], (2017),
[37]
P. Schuetz, L. Daniels, P. Kulkarni, S. Anker, B. Mueller.
Procalcitonin: A new biomarker for the cardiologist.
Int J Cardiol, 223 (2016), pp. 390-397
[38]
I. Iankova, P.H. Thompson, N. Kirson, B. Rice, J. Hey, A. Krause, et al.
Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: A systematic review and meta-analysis.
Critical Care Med, 46 (2018), pp. 691-698
[39]
D.J. Pepper, J. Sun, C. Rhee, J. Welsh, J.H. Powers, R.L. Danner, et al.
Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults. A systematic review and meta-analysis.
Chest, 155 (2019), pp. 1109-1118
[40]
T. Zhang, Y. Wang, Q. Yang, Y. Dong.
Procalcitonin-guided antibiotic therapy in critically ill adults: A meta-analysis.
BMC Infect Dis, 17 (2017), pp. 514
[41]
H.B. Huang, J.M. Peng, L. Weng, C.Y. Wang, W. Jiang, B. Du.
Procalcitonin-guided antibiotic therapy in intensive care unit patients: A systematic review and meta-analysis.
Annals of intensive care, 7 (2017), pp. 114
